These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27139372)

  • 1. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression.
    Feng Z; Wen H; Bi R; Ju X; Chen X; Yang W; Wu X
    Sci Rep; 2016 May; 6():25408. PubMed ID: 27139372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.
    Tan J; Song C; Wang D; Hu Y; Liu D; Ma D; Gao Q
    Biosci Rep; 2021 May; 41(5):. PubMed ID: 33891016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    Oncotarget; 2017 May; 8(20):32848-32855. PubMed ID: 28416763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
    Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
    J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
    J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
    Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
    Ajani MA; Salami A; Awolude OA; Oluwasola AO
    Pan Afr Med J; 2017; 27():259. PubMed ID: 29187928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.
    Lau KM; Mok SC; Ho SM
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5722-7. PubMed ID: 10318951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
    Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
    Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
    Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptors in breast cancer: more than estrogen receptors.
    Lamb CA; Vanzulli SI; Lanari C
    Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
    Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS
    Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.